Asparaginase is an enzyme that breaks down asparagine. Asparaginase is used as a chemotherapy drug to treat acute lymphoblastic leukemia (ALL), lymphoblastic lymphoma (LBL), and certain other blood cancers. Unlike normal cells, ALL cells are unable to make their own asparagine. Therefore, asparaginase stops the cancer cells from dividing and growing. Asparaginase enzyme is derived from Escherichia coli, Erwinia chrysanthemi, pegylated asparaginase, fungi, algae, and others. It is also used in the food processing industry for the reduction of acrylamide to ensure the food safety. The rising incidence of leukemia and significant growth of pharmaceutical and food industry are driving the growth of the asparaginase market.
Jazz Pharmaceutical Plc and Servier Pharmaceuticals LLC – Notable Market Players in Asparaginase Market
The Asparaginase market majorly consists of the players such as Jazz Pharmaceuticals, Inc., Servier Pharmaceuticals LLC, Medac GmbH, Porton Biopharma, Creative Enzymes, Biovendor LLC, Taj Pharmaceuticals Limited, Changzhou Qianhong Biopharma Co Ltd., and United Biotech. The companies have been implementing various strategies that have helped the growth of the company and in turn have brought about various changes in the market. The companies have utilized strategies such as product launches, expansions, and product upgradations for the growth of their organizations. The companies have adopted several inorganic and organic strategies to accelerate their growth and improve their market position.
Below is the list of the growth strategies done by the players operating in the Asparaginase market:
| Year | News |
| 2021 | Rylaze a multi-agent chemotherapeutic regimen for the treatment of patients with ALL or LBL in pediatric and adult patients one month and older was launched by Jazz Pharmaceuticals in the United States. |
| 2021 | Erwinase manufactured and licensed by Porton Biopharma in the UK is available for UK orders through Clinigen. |
| 2020 | Porton Biopharma has signed a worldwide licensing agreement with Clinigen Group plc for the distribution of Erwinase for the treatment of acute lymphoblastic leukemia. |
| 2021 | Rylaze manufactured by Jaaz Pharmaceutical is a multi-agent chemotherapeutic regimen for the treatment of patients with ALL or LBL in pediatric and adult patients one month and older who have developed hypersensitivity to E. coli-derived asparaginase was approved by FDA. |
